Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. Obstetrics & Gynecology 2019;134:899-908.
What it found
Sexual desire improved and related distress fell compared with placebo in both trials. Nausea was the most common side effect.
Limitations
Premenopausal women with acquired HSDD only. Critics have described the absolute size of the benefit as modest.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.